�鶹��ý

Awards and Recognition

• Recognized by The Legal 500 for her patent prosecution work, including reexamination and post-grant proceedings (2016-2017), and patent licensing and transactional work (2012)

Presentations and Publications

• “Recent Trends and Cases in Patent Prosecution” and “Pharma & Biotech Breakout: Patent Strategies for the New Administration and New Generation of Pharmaceuticals and Biologics,” �鶹��ý’s 2025 Tokyo IP Conference: Managing Risks and Opportunities in a Digital World – The Latest Developments in U.S. IP Law, Tokyo, Japan, October 8, 2025
• “Pharma & Biotech Breakout: In re Cellect and the Effect of Obviousness-Type Double Patenting on Patent Term Adjustment, Strategies for Prosecuting Orange Book-Listable Patents in an Era of Heightened FTC Scrutiny, and New Terminal Disclaimer Rules Proposed by the U.S. Patent and Trademark Office,” �鶹��ý’s 2024 Tokyo IP Conference: Navigating the Business of Innovation – Insights on Patent Eligibility, AI, and Other Key IP Developments, Tokyo, Japan, September 25, 2024
• “Recent Major Case Law Including the Amgen Patent Case Before the U.S. Supreme Court,” �鶹��ý & Lardner and Lee & Ko Joint Seminar, Korea Pharmaceutical and Bio-Pharma Manufacturers Association, Seoul, South Korea, September 26, 2023
• “Developments on U.S. Pharma Patent Prosecution & Policy During COVID-19,” Japan Pharmaceutical Manufacturers Association, U.S. Patent Law Seminar Series – 2020-2022, November 16, 2022
• “Important Developments at the U.S. Patent Trial and Appeal Board (PTAB),” Japan Intellectual Property Association, U.S. Intellectual Property Law Update Seminar Series – First Half of 2022, September 22, 2022
• “COVID-19 – Preparing for Post-Pandemic Transformation in Health Care and Life Sciences,” �鶹��ý Webinar, May 21, 2020
• “Responding to COVID 19 – Rapid Development and Launch Strategies for Diagnostics, Vaccines, and Therapeutics in a Global Pandemic,” �鶹��ý Webinar, March 26, 2020
• “Digital Health & Technology – Issues and Risk Management,” American Chamber of Commerce in Korea (AMCHAM) Joint Legal Affairs and Population Health & Technology Committee Meeting, Seoul, South Korea, August 8, 2019
• “Patent Eligibility: Understanding How New 101 Decisions are Impacting the Industry,” American Conference Institute (ACI) Women Leaders in Life Sciences Law 2019 Conference, Boston, MA, July 25, 2019
• “Biosimilars in the U.S., FDA Biosimilar Action Plan and Patent Challenges,” BIO KOREA 2019 International Convention, Seoul, South Korea, April 18, 2019
• “AI in the Pharmaceutical & Life Sciences Industry” and “IP Issues Related to the Integration of AI Into Pharma Research, Diagnostics & Digital Healthcare,” Japan Pharmaceutical Manufacturers Association, Tokyo, Japan, December 20, 2018
• “Immunotherapy at the Crossroads: Will Shifting Patent and Regulatory Trends Help or Hurt?,” South San Francisco, CA, November 27, 2018
• “Artificial Intelligence: The Next Technology Wave and Patent Strategies to Consider to Not Be Left Behind” and “’Pharma & Biotech Breakout: Advanced Strategy for Protecting Personalized Medicine Inventions Based on The USPTO’s 2018 Vanda Guidance, FDA Labeling Requirements & New Joint Infringement Precedent / Updates on the CRISPR Patent Interference,” �鶹��ý’s 2018 Tokyo IP Conference: Global Relationships in Flux – How Would You Redraw Your IP Strategy Map? Tokyo, Japan, October 11, 2018
• “FDA Biosimilar Action Plan & Current IP Issues,” Changes in U.S. Biosimilar Market Seminar, Seoul, South Korea, September 2018
• “The Use of Artificial Intelligence in Life Sciences/Healthcare and Licensing Considerations,” American Chamber of Commerce in Korea (AMCHAM) Joint Legal Affairs, Pharmaceuticals and Medical Devices Committee Meeting, Seoul, South Korea, May 9, 2018
• “AI on the Move: Tackling Legal Challenges with Artificial Intelligence in High-Tech and Life Sciences,” Osaka, March 14, 2018/Tokyo, March 15, 2018
• “Game Changers: How CAR-T and Cell Therapy Are Revolutionizing Cancer Immunotherapy,” �鶹��ý Webinar, December 7, 2017
• “’Pharma & Biotech Breakout:’ Hatch-Waxman and IPR Strategy Updates,” �鶹��ý’s 2017 Tokyo IP Conference: Global Impacts in Flux: Strategies for IP and Legal Leaders,” Tokyo, Japan, September 7, 2017
• “Biotech Protection in the U.S., Canada, and EU: Is This a New Era?,” 2017 BIO World Congress, Montréal, Canada, July 24, 2017
• “PTAB Practice Updates for Pharma and Biotech Companies,” MIP PTAB Forum 2017, New York, NY, May 16, 2017
• “Thought Leaders Exchange for Regenerative Medicine and Cell Therapy: Bridging the Gap Between Spectacular Medical Promises and Business Realities,” Boston, MA, May 3, 2017
• “U.S. Investment Strategies for Korean Life Sciences Firms,” SelectUSA Seminar at 2017 BIO KOREA, Seoul, South Korea, April 13, 2017
• “Optimizing Use of Inter Partes Review (IPR) and Ex Parte Reexaminations as a Commercialization Strategy for Biologics and Biosimilars in the U.S.,” AMCHAM Joint Legal Affairs and Pharmaceutical Committee Meeting, Seoul, South Korea, March 16, 2017
• “IPR Master Class Workshop Series – Session Two,” Tokyo, January 26, 2017
• “CRISPR-Cas – Patent, Licensing and Recent Development,” �鶹��ý and Japan Bioindustry Association CRISPR Seminar, Tokyo, January 25, 2017
• “IP Today: Capturing the Competitive Edge – Weighing the Impact of Change in the U.S. IP World,” Tokyo, September 8, 2016
• “IP Today: Capturing the Competitive Edge: U.S. Patent Prosecution Seminar Series,” Tokyo, June 30, 2016/Osaka, July 1, 2016
• “Supreme Court Declines to Review Sequenom Ruling,” Legal News: Intellectual Property, June 27, 2016
• “Pharma & the PTAB,” PTAB Forum 2016, May 12, 2016
• “The U.S. Market and Beyond: New IP Strategies for Success,” IP Today: Capturing the Competitive Edge Japan Program Series, Tokyo, Japan, September 29, 2015
• “The Road Ahead For Kyle Bass’s IPRs” Law360, August 2015
• “Federal Circuit Holds Sequenom’s Diagnostic Method Patent Invalid Under 101,” �鶹��ý & Lardner Legal News: Life Sciences, June 2015
• “Patent Watch: Have the Biosimilar Floodgates Been Opened in the United States?,” Nature Review, April 2015
• “IP on the Cusp of the Next Evolution,” IP in the Reform Era 2014 Seminar Series, Tokyo, Japan, September 9, 2014
• “America Invents Act: Law & Analysis,” Co-author, Wolters Kluwer Law & Business, 2014 Edition
• “USPTO Finally Issues New Guidance on Patent Subject Matter Eligibility,” PharmaPatents, December 2014
• “USPTO Issues Long–Awaited Revised Guidance on Patent Eligibility,” �鶹��ý & Lardner Legal News: Intellectual Property, December 2014
• “USPTO Issues New Guidelines on Subject Matter Eligibility Under 35 USC 101 in View of Myriad and Prometheus,” �鶹��ý & Lardner Legal News: Intellectual Property, March 2014
• “Supreme Court Holds Isolated Naturally Occurring DNA Cannot Be Patented, Sustains Patent-Eligibility of cDNA,” �鶹��ý & Lardner Legal News: Intellectual Property, June 2013
• “Federal Circuit Again Upholds Patent-Eligibility of Myriad’s Isolated DNA Claims, Holds Diagnostic “Analyzing” Claims Patent-Ineligible,” �鶹��ý & Lardner Legal News: Intellectual Property, August 2012
• “Unanimous Supreme Court Invalidates Prometheus Personalized Medicine Claims,” �鶹��ý & Lardner Legal News: Life Sciences, March 2012
• “The Biologics Price Competition and Innovation Act: Implications for Implementation in Light of FDA Draft Guidance,” �鶹��ý & Lardner Legal News: Life Sciences, February 2012
• “USPTO Issues Proposed Rules Packages to Implement America Invents Act,” �鶹��ý & Lardner Legal News: Intellectual Property, February 2012